Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of race on mutational profile and survival in acute myeloid leukemia: a single-institution experience (2014-2024).

Annals of hematology·2026
Same author

Spatial remodeling of bone marrow architecture defines tissue-state signatures of disease activity and therapeutic response in myelodysplastic neoplasms.

Leukemia·2026
Same author

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

Limited prognostic value of ELN classification and relevance of molecular ontogeny in acute myeloid leukemia post myeloproliferative neoplasms: a retrospective multicenter study.

Acta haematologica·2026
Same author

CMML is in the eye of the be-WHO-lder: interrogating the newly proposed entity of oligomonocytic CMML: MDS or CMML?

Blood neoplasia·2026

Related Experiment Video

Updated: Dec 28, 2025

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

12.2K

Decoding Bone Marrow Fibrosis in Myelodysplastic Syndromes.

Megan Melody1, Najla Al Ali1, Ling Zhang2

  • 1Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Clinical Lymphoma, Myeloma & Leukemia
|February 12, 2020
PubMed
Summary

Severe bone marrow fibrosis (BMF) in myelodysplastic syndromes (MDS) significantly reduces overall survival, independent of risk scores. However, BMF grade does not impact treatment response to hypomethylating agents or lenalidomide.

Keywords:
IPSS-RMDSMarrow fibrosisOutcomesSomatic mutations

More Related Videos

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.7K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.0K

Related Experiment Videos

Last Updated: Dec 28, 2025

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

12.2K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.7K
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

10.0K

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Bone marrow fibrosis (BMF) is a poor prognostic indicator in myelodysplastic syndromes (MDS).
  • The prognostic impact of BMF, especially severe BMF, within current MDS risk stratification systems requires further investigation.

Purpose of the Study:

  • To investigate the association between BMF in MDS and patient survival outcomes.
  • To explore the spectrum of somatic gene mutations in MDS patients with varying degrees of BMF.

Main Methods:

  • Retrospective analysis of 2624 MDS patients categorized by BMF grade (0-2 vs. 3).
  • Comparison of somatic gene mutations using next-generation sequencing data between BMF groups.
  • Evaluation of survival outcomes and treatment responses.

Main Results:

  • Severe (grade 3) BMF was independently associated with worse overall survival (HR=1.6).
  • Patients with severe BMF had higher-risk classifications (MDS-EB, higher IPSS-R) and more frequent TP53 and SETBP1 mutations.
  • No significant difference in response to hypomethylating agents or lenalidomide was observed based on BMF grade.

Conclusions:

  • Grade 3 BMF is an independent predictor of reduced survival in MDS patients.
  • TP53 and SETBP1 mutations are more prevalent in MDS with severe fibrosis.
  • BMF severity does not influence the efficacy of standard MDS therapies like hypomethylating agents or lenalidomide.